Trials in progress: IMagyn050/GOG 3015/ENGOT-OV39. A Phase III, multicenter, randomized study of atezolizumab versus placebo administered in combination with paclitaxel, carboplatin, and bevacizumab to patients with newly-diagnosed stage III or stage IV ovarian, fallopian tube, or primary peritoneal cancer

K.N. Moore; S. Pignata

doi:10.1136/ijgc-2018-000071

Trials in progress: IMagyn050/GOG 3015/ENGOT-OV39. A Phase III, multicenter, randomized study of atezolizumab versus placebo administered in combination with paclitaxel, carboplatin, and bevacizumab to patients with newly-diagnosed stage III or stage IV ovarian, fallopian tube, or primary peritoneal cancer

Istituto Nazionale Tumori Fondazione G. Pascale

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	430-433
Number of pages	4
Journal	International Journal of Gynecological Cancer
Volume	29
Issue number	2
DOIs	https://doi.org/10.1136/ijgc-2018-000071
Publication status	Published - 2019

Access to Document

10.1136/ijgc-2018-000071

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85066476705&doi=10.1136%2fijgc-2018-000071&partnerID=40&md5=7e04bbb32e5ae386403cfca35e1e96c0

Cite this

Moore, K. N., & Pignata, S. (2019). Trials in progress: IMagyn050/GOG 3015/ENGOT-OV39. A Phase III, multicenter, randomized study of atezolizumab versus placebo administered in combination with paclitaxel, carboplatin, and bevacizumab to patients with newly-diagnosed stage III or stage IV ovarian, fallopian tube, or primary peritoneal cancer. International Journal of Gynecological Cancer, 29(2), 430-433. https://doi.org/10.1136/ijgc-2018-000071

Trials in progress: IMagyn050/GOG 3015/ENGOT-OV39. A Phase III, multicenter, randomized study of atezolizumab versus placebo administered in combination with paclitaxel, carboplatin, and bevacizumab to patients with newly-diagnosed stage III or stage IV ovarian, fallopian tube, or primary peritoneal cancer. / Moore, K.N.; Pignata, S.

In: International Journal of Gynecological Cancer, Vol. 29, No. 2, 2019, p. 430-433.

Research output: Contribution to journal › Article › peer-review

Moore, KN & Pignata, S 2019, 'Trials in progress: IMagyn050/GOG 3015/ENGOT-OV39. A Phase III, multicenter, randomized study of atezolizumab versus placebo administered in combination with paclitaxel, carboplatin, and bevacizumab to patients with newly-diagnosed stage III or stage IV ovarian, fallopian tube, or primary peritoneal cancer', International Journal of Gynecological Cancer, vol. 29, no. 2, pp. 430-433. https://doi.org/10.1136/ijgc-2018-000071

Moore KN, Pignata S. Trials in progress: IMagyn050/GOG 3015/ENGOT-OV39. A Phase III, multicenter, randomized study of atezolizumab versus placebo administered in combination with paclitaxel, carboplatin, and bevacizumab to patients with newly-diagnosed stage III or stage IV ovarian, fallopian tube, or primary peritoneal cancer. International Journal of Gynecological Cancer. 2019;29(2):430-433. https://doi.org/10.1136/ijgc-2018-000071

Moore, K.N. ; Pignata, S. / Trials in progress: IMagyn050/GOG 3015/ENGOT-OV39. A Phase III, multicenter, randomized study of atezolizumab versus placebo administered in combination with paclitaxel, carboplatin, and bevacizumab to patients with newly-diagnosed stage III or stage IV ovarian, fallopian tube, or primary peritoneal cancer. In: International Journal of Gynecological Cancer. 2019 ; Vol. 29, No. 2. pp. 430-433.

@article{6ecb8952171d4d12a690bbd99ce2e52f,

title = "Trials in progress: IMagyn050/GOG 3015/ENGOT-OV39. A Phase III, multicenter, randomized study of atezolizumab versus placebo administered in combination with paclitaxel, carboplatin, and bevacizumab to patients with newly-diagnosed stage III or stage IV ovarian, fallopian tube, or primary peritoneal cancer",

author = "K.N. Moore and S. Pignata",

note = "Cited By :1 Export Date: 16 July 2019",

year = "2019",

doi = "10.1136/ijgc-2018-000071",

language = "English",

volume = "29",

pages = "430--433",

journal = "International Journal of Gynecological Cancer",

issn = "1048-891X",

publisher = "Lippincott Williams and Wilkins",

number = "2",

}

TY - JOUR

T1 - Trials in progress: IMagyn050/GOG 3015/ENGOT-OV39. A Phase III, multicenter, randomized study of atezolizumab versus placebo administered in combination with paclitaxel, carboplatin, and bevacizumab to patients with newly-diagnosed stage III or stage IV ovarian, fallopian tube, or primary peritoneal cancer

AU - Moore, K.N.

AU - Pignata, S.

N1 - Cited By :1 Export Date: 16 July 2019

PY - 2019

Y1 - 2019

U2 - 10.1136/ijgc-2018-000071

DO - 10.1136/ijgc-2018-000071

M3 - Article

VL - 29

SP - 430

EP - 433

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 2

ER -